Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

HIV Infection

Free Subscription Articles published in Vaccine Retrieve available abstracts of 67 articles: HTML format

Single Articles

October 2025
1. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
   Corrigendum to "Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort" [Vaccine 62 (2025) 127580].
   Vaccine. 2025;67:127855.
   PubMed    
   
   
   
2. COLLINS C, Ratshisusu L, Modise LM, Simani OE, et al
   Hepatitis B virus infection and vaccine coverage among children living with HIV, HIV-exposed uninfected, and HIV-unexposed uninfected children in the Western Cape, South Africa.
   Vaccine. 2025;66:127843.
   PubMed     Abstract available
   
   
   
3. IVERSEN EF, Rahimic AHF, Frattari GS, Rosas-Umbert M, et al
   TCR bias drives development of dominant vaccine-induced CD8+ T cell responses which can be redirected toward cellular targets.
   Vaccine. 2025;66:127851.
   PubMed     Abstract available
   
   
   
4. RACCAGNI AR, Morsica G, Reali P, Lolatto R, et al
   Long-term protection and response to a booster dose after primary hepatitis B vaccination in people under pre-exposure prophylaxis for HIV infection.
   Vaccine. 2025;66:127825.
   PubMed     Abstract available
   
   
   
5. CLAY PA, Markowitz LE, Gopalani SV, Baxter A, et al
   HPV vaccination among gay, bisexual, and other men who have sex with men aged 27-45 years in the United States is potentially Cost-saving.
   Vaccine. 2025;65:127798.
   PubMed     Abstract available
   
   
   
6. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
   Corrigendum to "Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa" [Vaccine 64 (2025) 127770].
   Vaccine. 2025;65:127797.
   PubMed    
   
   
   September 2025
7. VAN SCHALKWYK C, Meyer-Rath G, Masuku S, Jamieson L, et al
   Cost-effectiveness of different HPV vaccination strategies for cervical cancer prevention in South Africa.
   Vaccine. 2025;64:127770.
   PubMed     Abstract available
   
   
   
8. ARSUFFI S, Rossi L, Colombo FR, Inverardi M, et al
   Herpes zoster reactivation in a cohort of people living with HIV vaccinated with recombinant vaccine.
   Vaccine. 2025;64:127723.
   PubMed     Abstract available
   
   
   
9. BOGA DJ, Robinson M, Tirupathi M, Juste RS, et al
   Latent class and time-to-event analyses of social determinants of health and COVID-19 vaccine uptake among Black women living with HIV.
   Vaccine. 2025;64:127649.
   PubMed     Abstract available
   
   
   August 2025
10. BARLOW M, Flanagan S, Ghosh I, Carter J, et al
    Offering Hepatitis B vaccination to vulnerable populations: How can we plug the gaps?
    Vaccine. 2025;63:127639.
    PubMed    
    
    
    
11. YOU D, Quan J, Bishai D, Lam WWT, et al
    Evaluating cost-effectiveness of 9-valent HPV vaccination for men who have sex with men by HIV status in Hong Kong.
    Vaccine. 2025;63:127625.
    PubMed     Abstract available
    
    
    
12. YAMEY G, Beyrer C
    The dismantling of the U.S. vaccine regulatory framework.
    Vaccine. 2025;62:127557.
    PubMed    
    
    
    
13. GAO L, Zhang X, Mo X, Sun Y, et al
    Duration of immunogenicity of four triple doses and four standard doses hepatitis B vaccine in adults infected with human immunodeficiency virus: A one-year follow-up study in China.
    Vaccine. 2025;62:127596.
    PubMed     Abstract available
    
    
    
14. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.
    Vaccine. 2025;62:127580.
    PubMed     Abstract available
    
    
    July 2025
15. EXCLER JL, Saluja T, Wilder-Smith A, Kaminski RW, et al
    Non-typhoidal Salmonella combination vaccines: clinical development plan and regulatory considerations.
    Vaccine. 2025;62:127515.
    PubMed     Abstract available
    
    
    
16. CARDENAS-GARZON K, Agudelo MC, Tovar-Aguirre OL, Reuter C, et al
    Understanding the decline in HPV vaccination in Colombia: A population-based analysis of girls and parents in early rollout cohorts.
    Vaccine. 2025;62:127507.
    PubMed     Abstract available
    
    
    
17. MURATA M, Matsumoto Y, Shimono N
    Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1.
    Vaccine. 2025;62:127457.
    PubMed     Abstract available
    
    
    
18. GIULIANO AR, Beltrame A, Villa LL, Lazcano-Ponce E, et al
    Design of a multicenter, randomized, double-blinded, placebo-controlled phase III trial evaluating the 9-valent human papillomavirus (HPV) vaccine to prevent persistent oral HPV infection in men living with human immunodeficiency virus: ULACNet trial
    Vaccine. 2025;61:127447.
    PubMed     Abstract available
    
    
    
19. FREITAS C, Cooper CL, Kroch AE, Moineddin R, et al
    COVID-19 vaccine uptake in a retrospective population-based cohort of people living with and without HIV in Ontario, Canada.
    Vaccine. 2025;61:127422.
    PubMed     Abstract available
    
    
    June 2025
20. JOLFAYI AG, Alipour S, Aminizadeh S, Yaghoubi SM, et al
    Dendritic cell-based vaccines, a promising prospect for ending AIDS and eradication of HIV worldwide: A narrative review on the latest updates.
    Vaccine. 2025;61:127340.
    PubMed     Abstract available
    
    
    May 2025
21. ANYANGO RO, Nyawanda BO, Onyando BO, Haidara FC, et al
    Factors associated with laboratory-confirmed SARS-Cov-2 infection among patients with severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 May 12:127234. doi: 10.1016/j.vaccine.2025.127234.
    PubMed     Abstract available
    
    
    
22. MASHAMBA M, Msibi T, Tshabalala G, Tsotetsi L, et al
    Factors influencing influenza vaccine uptake among adults in Johannesburg, South Africa: A qualitative study.
    Vaccine. 2025;57:127133.
    PubMed     Abstract available
    
    
    April 2025
23. MCGRATH LJ, Khan FL, Lopez SMC, Brouillette MA, et al
    2023-2024 COVID-19 vaccine uptake among immunocompromised individuals in two US states.
    Vaccine. 2025;56:127120.
    PubMed     Abstract available
    
    
    
24. JOHNSTONE SL, Shapiro D, Chiwandire N, Matoti L, et al
    Effectiveness of BNT162b2 and Ad26.COV2.S vaccines against COVID-19-related hospitalisation amongst adult members of a private health insurance plan in South Africa during the Delta and Omicron periods: A test-negative case-control study.
    Vaccine. 2025 Apr 2:127068. doi: 10.1016/j.vaccine.2025.127068.
    PubMed     Abstract available
    
    
    
25. STRONG C, Joson P, Chu IY, Chuang TT, et al
    Prioritization and barriers of mpox vaccination uptake among gay, bisexual and other men who have sex with men in Taiwan: 2023 HEART survey.
    Vaccine. 2025;53:127059.
    PubMed     Abstract available
    
    
    March 2025
26. TIRUNEH YM, Choi J, Cuccaro PM, Martinez J, et al
    Sociodemographic and health-related predictors of COVID-19 booster uptake among fully vaccinated adults.
    Vaccine. 2025;54:127048.
    PubMed     Abstract available
    
    
    
27. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    PubMed     Abstract available
    
    
    
28. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    PubMed     Abstract available
    
    
    
29. EMARY K, Bentsi-Enchill AD, Giersing BK, Gordon M, et al
    Landscape analysis of invasive non-typhoidal salmonella (iNTS) disease and iNTS vaccine use case and demand: Report of a WHO expert consultation.
    Vaccine. 2025;55:127008.
    PubMed     Abstract available
    
    
    
30. MACGIBBON J, Storer D, Bavinton BR, Cornelisse VJ, et al
    Mpox vaccination coverage among Australian gay and bisexual men and non-binary people: Results of behavioural surveillance in early 2024.
    Vaccine. 2025;55:127014.
    PubMed     Abstract available
    
    
    
31. ONYANDO BO, Nyawanda BO, Onguru D, Haidara FC, et al
    Factors associated with mortality among patients aged 12 years and above requiring hospitalization for severe respiratory illness (SRI): Findings from the COVID-19 vaccine effectiveness evaluation in Kenya and Mali, 2022-2023.
    Vaccine. 2025 Mar 1:126910. doi: 10.1016/j.vaccine.2025.126910.
    PubMed     Abstract available
    
    
    February 2025
32. COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
    Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
    Vaccine. 2025;49:126778.
    PubMed     Abstract available
    
    
    
33. SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
    Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
    Vaccine. 2025;50:126846.
    PubMed     Abstract available
    
    
    
34. MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
    Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
    Vaccine. 2025;50:126818.
    PubMed     Abstract available
    
    
    
35. JENNINGS MC, Nabia S, Morgan C, Nduka CC, et al
    Realist review of low- to upper-middle-income country experiences on integration of HPV vaccination with other adolescent health services.
    Vaccine. 2025;50:126833.
    PubMed     Abstract available
    
    
    January 2025
36. GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
    Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
    Vaccine. 2025;49:126777.
    PubMed     Abstract available
    
    
    
37. KAUL R, Leidner AJ, Chesson HW
    Trends in costs of routinely recommended vaccines in the United States, 2001-2023.
    Vaccine. 2025;47:126667.
    PubMed     Abstract available
    
    
    December 2024
38. PEREZ-SAUCEDO D, Castro-Perea NV, Ruiz-Cruz A, Bustos-Jaimes I, et al
    Design and evaluation of a multi-epitope HIV-1 vaccine based on human parvovirus virus-like particles.
    Vaccine. 2024;45:126663.
    PubMed     Abstract available
    
    
    
39. KASSAM P, El-Zein M, Tota JE, Tellier PP, et al
    HPV vaccination and anal HPV infection in gay, bisexual, and other men who have sex with men.
    Vaccine. 2024;45:126644.
    PubMed     Abstract available
    
    
    
40. SANKAR C, Meyer JC, Schonfeldt M, Gunter H, et al
    Vaccine safety surveillance in South Africa through COVID-19: A journey to systems strengthening.
    Vaccine. 2024 Dec 6:126535. doi: 10.1016/j.vaccine.2024.126535.
    PubMed     Abstract available
    
    
    October 2024
41. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    PubMed     Abstract available
    
    
    
42. TRAVILL DI, Machalek DA, Rees H, Mbulawa Z, et al
    High prevalence of human papillomavirus (HPV) in unvaccinated adolescent girls in South Africa, particularly those living with HIV.
    Vaccine. 2024;42:126442.
    PubMed     Abstract available
    
    
    
43. EARP M, Meng L, Black CL, Carter RJ, et al
    Using regression tree analysis to examine demographic and geographic characteristics of COVID-19 vaccination trends over time, United States, May 2021-April 2022, National Immunization Survey Adult COVID Module.
    Vaccine. 2024;42:126372.
    PubMed     Abstract available
    
    
    September 2024
44. WITTESAELE C, Toska E, Cluver L, Weiss HA, et al
    Vaccine coverage and timeliness among children of adolescent mothers: A community-based study in the eastern cape, South Africa.
    Vaccine. 2024;42:126318.
    PubMed     Abstract available
    
    
    
45. KRAUSE KD, D'Avanzo PA, Karr AG, Rhem C, et al
    Vaccination uptake in LGBTQ adults in two US states: Findings from the QVax study.
    Vaccine. 2024;42:126320.
    PubMed     Abstract available
    
    
    August 2024
46. NAVARRO-TORNE A, Anderson A, Panwar K, Ghys E, et al
    How has post-implementation surveillance of high-coverage vaccination with HPV16/18-AS04 vaccine in England added to evidence about its cross-protective effects?
    Vaccine. 2024;42:126215.
    PubMed     Abstract available
    
    
    
47. GUZMAN RUIZ L, Zollner AM, Hoxie I, Kuchler J, et al
    Enhancing NA immunogenicity through novel VLP designs.
    Vaccine. 2024;42:126270.
    PubMed     Abstract available
    
    
    
48. GEORGE G, Strauss M, Lansdell E, Nota P, et al
    Factors associated with COVID-19 vaccine uptake among south African health care workers.
    Vaccine. 2024;42:126181.
    PubMed     Abstract available
    
    
    July 2024
49. JOHNSTON C, Scheele S, Bachmann L, Boily MC, et al
    Vaccine value profile for herpes simplex virus.
    Vaccine. 2024;42.
    PubMed     Abstract available
    
    
    
50. MARTIN LB, Tack B, Marchello CS, Sikorski MJ, et al
    Vaccine value profile for invasive non-typhoidal Salmonella disease.
    Vaccine. 2024;42.
    PubMed     Abstract available
    
    
    
51. HU TH, Tou CY, Lee YH, Chang HH, et al
    Knowledge gap of human monkeypox among high-risk individuals receiving preexposure vaccination in Taiwan.
    Vaccine. 2024 Jul 16:S0264-410X(24)00753-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    June 2024
52. YOUNES S, Nicolai E, Younes N, Pieri M, et al
    Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Vaccine. 2024 Jun 5:S0264-410X(24)00669-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    May 2024
53. NAKASE T, Brownwright T, Okunromade O, Egwuenu A, et al
    The impact of sub-national heterogeneities in demography and epidemiology on the introduction of rubella vaccination programs in Nigeria.
    Vaccine. 2024 May 28:S0264-410X(24)00589-9. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
54. BATOOL R, Yousafzai MT, Mir F, Muhammad S, et al
    Longevity of serologic responses following a single dose of typhoid conjugate vaccine among children living with HIV in Pakistan: A prospective cohort study.
    Vaccine. 2024 May 28:S0264-410X(24)00625-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
55. YEGANEH N, Yin S, Moir O, Danza P, et al
    Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023.
    Vaccine. 2024 May 23:S0264-410X(24)00594-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
56. CHIHANA R, Jin Kee J, Moodie Z, Huang Y, et al
    Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
    Vaccine. 2024 May 21:S0264-410X(24)00598-X. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
57. GRIFFIN I, Berry I, Navarra T, Priyamvada L, et al
    Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.).
    Vaccine. 2024 May 17:S0264-410X(24)00563-2. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
58. KOLAKOWSKA A, Marshall E, Krastinova E, Cros A, et al
    Insufficient vaccine coverage and vaccine hesitancy in people living with HIV: A prospective study in outpatient clinics in the Paris region.
    Vaccine. 2024 May 6:S0264-410X(24)00516-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    April 2024
59. TRINITE B, Durr E, Pons-Grifols A, O'Donnell G, et al
    VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Vaccine. 2024 Apr 18:S0264-410X(24)00473-0. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
60. SUKIK L, Chemaitelly H, Ayoub HH, Coyle P, et al
    Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradient.
    Vaccine. 2024 Apr 13:S0264-410X(24)00440-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
61. CERNUSCHI T, Malvolti S, Hall S, Debruyne L, et al
    The quest for more effective vaccine markets - Opportunities, challenges, and what has changed with the SARS-CoV-2 pandemic.
    Vaccine. 2024;42 Suppl 1:S64-S72.
    PubMed     Abstract available
    
    
    March 2024
62. CHEUNG DH, Chen S, Fang Y, Sun F, et al
    Influences of mpox disease perceptions, sources and contents of information exposure on mpox vaccine uptake among gay, bisexual, and other men who have sex with men in Hong Kong, China.
    Vaccine. 2024 Mar 12:S0264-410X(24)00259-7. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
63. MENG L, Harris L, Shaw L, Lymon H, et al
    Social and demographic factors associated with receipt of a COVID-19 vaccine initial booster dose and with interval between primary series completion and initial booster dose uptake among persons aged >/= 12 years, United States, August 2021-October 2
    Vaccine. 2024 Mar 6:S0264-410X(24)00271-8. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
64. BEAVIS AC, Dienger-Stambaugh K, Briggs K, Chen Z, et al
    A J Paramyxovirus-vectored HIV vaccine induces humoral and cellular responses in mice.
    Vaccine. 2024 Mar 4:S0264-410X(24)00227-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    February 2024
65. YADEGARYNIA D, Keyvanfar A, Keyvani H, Tehrani S, et al
    Immunogenicity and safety of a quadrivalent recombinant influenza vaccine manufactured in Iran (FluGuard) in volunteers aged 18-60 years: A double-blind, non-inferiority, randomized controlled trial.
    Vaccine. 2024 Feb 29:S0264-410X(24)00249-4. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    
66. MARINDA E, Mathentamo Q, Coulson N, Parker S, et al
    Impact evaluation of a youth led intervention to increase COVID-19 vaccine uptake in Kwazulu-Natal, South Africa.
    Vaccine. 2024 Feb 28:S0264-410X(24)00211-1. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available
    
    
    December 2023
67. PICHON S, Moureau A, Petit C, Kirstein JL, et al
    Safety and immunogenicity of a serum-free purified Vero rabies vaccine in comparison with the rabies human diploid cell vaccine (HDCV; Imovax(R) Rabies) administered in a simulated rabies post-exposure regimen in healthy adults.
    Vaccine. 2023 Dec 16:S0264-410X(23)01398-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.